Literature DB >> 20334603

Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B.

Neeraj Mishra1, Shailja Tiwari, Bhuvaneshwar Vaidya, Govind P Agrawal, Suresh P Vyas.   

Abstract

Present study aimed at exploring the potential of α-l-fucose specific, LTA (Lotus tetragonolobus from Winged or Asparagus pea) as a homing device for nanocarriers to target the M cell for elicitation of strong immune response. LTA grafted poly(lactic-co-glycolic acids) (PLGA) nanoparticles encapsulating hepatitis B surface antigen (HBsAg) was developed and characterized for shape, size, polydispersity index, zeta potential, and antigen loading efficiency. The peyer's patch uptake was studied by using confocal laser scanning microscopy technique using dual staining technique. The immune stimulating potential was assessed by measuring anti-HBsAg titer in serum of balb/c mice. Induction of the mucosal immunity was assessed by estimating secretory immunoglobulin A level in the salivary, intestinal, and vaginal secretion and cytokine (interleukin-2 and interferon-γ) levels in the spleen homogenates. Furthermore, IgG1 and IgG2a isotype were determined to confirm the T(H)1/T(H)2 mixed immune response. The LTA anchored PLGA nanoparticles have demonstrated approximately four-fold increase in the degree of interaction with the bovine submaxillary mucin (BSM). The results demonstrated that LTA anchored PLGA nanoparticles elicited strong mucosal and systemic response and hence could be a promising carrier adjuvant for the M cell targeted oral mucosal immunization against Hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334603     DOI: 10.3109/10611861003733946

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  14 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses.

Authors:  David D Lo; Jun Ling; A Holly Eckelhoefer
Journal:  BMC Biotechnol       Date:  2012-03-13       Impact factor: 2.563

3.  Novel approaches to oral immunization for hepatitis B.

Authors:  Shailja Tiwari; Suresh P Vyas
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

4.  Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.

Authors:  Rasa Ghaffarian; Tridib Bhowmick; Silvia Muro
Journal:  J Control Release       Date:  2012-06-12       Impact factor: 9.776

5.  Histochemical and biochemical analysis of the size-dependent nanoimmunoresponse in mouse Peyer's patches using fluorescent organosilica particles.

Authors:  Aziz Awaad; Michihiro Nakamura; Kazunori Ishimura
Journal:  Int J Nanomedicine       Date:  2012-03-13

Review 6.  Demystifying particle-based oral vaccines.

Authors:  Pedro Gonzalez-Cruz; Harvinder Singh Gill
Journal:  Expert Opin Drug Deliv       Date:  2021-07-06       Impact factor: 8.129

7.  Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles.

Authors:  Kai Zhao; Wei Li; Tingting Huang; Xiaomei Luo; Gang Chen; Yang Zhang; Chen Guo; Chunxiao Dai; Zheng Jin; Yan Zhao; Hongyu Cui; Yunfeng Wang
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 8.  Use of lectin-functionalized particles for oral immunotherapy.

Authors:  Susanne C Diesner; Xue-Yan Wang; Erika Jensen-Jarolim; Eva Untersmayr; Franz Gabor
Journal:  Ther Deliv       Date:  2012-02

9.  Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy.

Authors:  Susanne C Diesner; Cornelia Bergmayr; Xue-Yan Wang; Denise Heiden; Sarah Exenberger; Franziska Roth-Walter; Philipp Starkl; Davide Ret; Isabella Pali-Schöll; Franz Gabor; Eva Untersmayr
Journal:  Clin Immunol       Date:  2018-03-30       Impact factor: 3.969

10.  Ganoderma lucidum polysaccharides counteract inhibition on CD71 and FasL expression by culture supernatant of B16F10 cells upon lymphocyte activation.

Authors:  Li-Xin Sun; Zhi-Bin Lin; Xin-Suo Duan; Jie Lu; Zhi-Hua Ge; Min Li; En-Hong Xing; Tian-Fei Lan; Miao-Miao Jiang; Ning Yang; Wei-Dong Li
Journal:  Exp Ther Med       Date:  2013-01-29       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.